Skip to main content
Clinical TrialsJuly 20201 min read

SPECTRE Phantom Enables Cross-Site MRS Calibration

Multi-site spectroscopy study demonstrates phantom-based standardisation for clinical trials

A 22-scanner study across 19 sites demonstrated that SPECTRE phantoms enable cross-calibration of MRS measurements, reducing variability and improving sensitivity for multi-site clinical trials in metachromatic leukodystrophy.

The challenge

A clinical trial in metachromatic leukodystrophy required Magnetic Resonance Spectroscopy (MRS) measurements across 19 sites with 22 scanners (6 at 1.5T, 16 at 3T). Multi-site imaging inevitably introduces variability that must be quantified and controlled to ensure comparability between sites and sensitivity to detect treatment effects.

The solution

Gold Standard Phantoms developed a series of SPECTRE (SPEctroscopy Reference) phantoms filled from the same chemical batch to replicate brain metabolite concentrations including NAA (12.5 mM), Creatine (10.0 mM), Choline (3.0 mM), Myo-inositol (7.5 mM), Glutamate (12.5mM), and Lactate (5.0 mM). Each site performed standardised single-voxel MRS sequences with three repeat acquisitions. Spectra were centrally analysed using LCModel and quality controlled by Bioclinica.

Supporting material
Download conference poster (PDF)
Bring this to your site

Run independent, longitudinal QA with SPECTRE.

MRS spectroscopy reference phantom for cross-site calibration.

Learn more about SPECTRERequest a demo
More case studies

Other stories from the field